Value of 8-iso-PG and endothelin detections in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease complicated with pulmonary hypertension
10.7619/jcmp.201709009
- VernacularTitle:8-异前列腺素、血管内皮素在慢性阻塞性肺疾病急性加重合并肺动脉高压患者中的应用价值
- Author:
Licheng ZHU
1
;
Yunfei SHANG
Author Information
1. 南通大学附属南通第三医院 呼吸科
- Keywords:
8-iso-PG;
ET-1;
chronic obstructive pulmonary disease;
pulmonary hypertension;
oxidative stress;
N-acetylcysteine
- From:
Journal of Clinical Medicine in Practice
2017;21(9):35-38
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of 8-iso-PG and endothelin (ET-1) detections in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with pulmonary hypertension (PAH).Methods A total of 40 AECOPD patients with pulmonary hypertension were randomly divided into treatment group and control group,anotheR20 COPD patients without pulmonary hypertension were selected as control group.According to the level of pulmonary arterial pressure,the patients were divided into subgroups,and correlation and changes of indexes were compared among groups.Results There were significant differences between the AECOPD group and combined PAH group in serum 8-iso-PG and endothelin levels (P<0.01).Correlation analysis showed that the levels of 8-iso-PG and ET-1 in the combined PAH group were not correlated with FVC,p(CO2) and FEV1 (P>0.05),but there was a negative lineaRcorrelation with p(O2) and was positively correlated with pulmonary artery pressure (P<0.05).There were significant differences in 8-iso-PG and ET-1 levels among different PAH groups (P<0.01).AfteRtreatment,levels of ET-1 and 8-iso-PG significantly reduced,FEV1 and FVC significantly increased (P<0.05),and the level of PASP reduced significantly in treatment group and control group (P<0.05).Conclusion 8-iso-PG can be used as a good markeRof oxidative stress,and the combined detection of 8-iso-PG and ET-1 can be used as a good index foRevaluating the severity and treatment of patients with AECOPD and PAH.
